1.22 Elo-Pom-Dex, Immunotherapy Combos, Inherent Bias, and the FDA with Dr. Erick Turner
Nov 13, 2018•1 hr 16 min
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
In this episode, we tackle the recent papers in the New England Journal of Medicine on "Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma" and "Immunotherapy Combinations in Multiple Myeloma", as well as a comment in The Lancet Oncology's editorial "9 Weeks That Matter for Patients With Gastric Cancer". We conclude with an interview with Dr. Erick Turner of OHSU on the FDA, regulatory capture, selective reporting, and transparency.
Elo-pom-dex: http://doi.org/10.1056/NEJMoa1805762
Immunotherapy combinations: http://doi.org/10.1056/NEJMp1803602
9 weeks that matter: http://doi.org/10.1016/S1470-2045(18)30752-6
Dr. Turner's seminal paper: https://doi.org/10.1056/NEJMsa065779
For the best experience, listen in Metacast app for iOS or Android
Open in Metacast